“The LOCATE study demonstrated that imaging with 18F fluciclovine PET/CT revealed one or more sites of disease recurrence in men with biochemically recurrent prostate cancer who were scanned, and based on the pattern of recurrence, resulted in a change in management after the scan in 59 percent of the patients.” {read more here}